Vivo Bio Tech Ltd.

Vivo Bio Tech . has reached a new 52-week low of Rs.29.21 today, marking a significant decline amid a sustained period of negative returns. The stock has been on a downward trajectory for the past ten trading sessions, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector.

Vivo Bio Tech . has reached a fresh 52-week low of Rs.29.21 today, marking a significant decline amid a sustained downward trend that has persisted over the past ten trading sessions. The stock’s performance contrasts sharply with broader market gains, reflecting ongoing challenges within the company’s financial and operational metrics.

Vivo Bio Tech . has reached a new 52-week low of Rs.30.11 today, marking a significant milestone in its ongoing downward trajectory. The stock has been on a losing streak for eight consecutive trading sessions, reflecting a cumulative return decline of 10.85% over this period, underperforming its sector by 0.29% on the day.

Vivo Bio Tech . has reached a new 52-week low of Rs.30.11 today, marking a significant decline amid an extended period of negative returns. The stock has recorded losses over the past eight consecutive trading sessions, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector.

Vivo Bio Tech . has reached a new 52-week low of Rs.30.11 today, marking a significant decline amid a sustained downward trend. The stock has recorded losses over the past eight consecutive trading sessions, reflecting a cumulative return of -10.85% during this period, underperforming its sector by 0.29% on the day.

Shares of Vivo Bio Tech . touched a fresh 52-week low of Rs.30.11 today, marking a significant milestone in the stock’s ongoing downward trajectory. The pharmaceutical and biotechnology company’s stock has been under pressure, reflecting a series of financial and market factors that have influenced its performance over the past year.

Vivo Bio Tech . has reached a new 52-week low of Rs.30.11 today, marking a significant milestone in its recent price movement. The stock has been on a downward trajectory for eight consecutive trading sessions, reflecting a cumulative return decline of 10.85% during this period, underperforming its sector by 0.29% on the day.

Vivo Bio Tech . has reached a new 52-week low of Rs.30.11 today, marking a significant decline amid an extended period of negative returns. The stock has been trading below all major moving averages and has recorded losses over the past eight consecutive sessions, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector.

Vivo Bio Tech . has reached a new 52-week low of Rs.30.11 today, marking a significant point in its recent trading performance. The stock has been on a downward trajectory for eight consecutive sessions, reflecting a cumulative return decline of 10.85% over this period, while underperforming its sector by 0.29% today.

Vivo Bio Tech . has reached a new 52-week low of Rs.30.99 today, marking a significant decline amid a sustained downward trend. The stock has underperformed its sector and broader market indices, reflecting ongoing concerns about its financial performance and valuation metrics.

Vivo Bio Tech . has reached a new 52-week low of Rs.30.99 today, marking a significant decline amid a sustained downward trend. The stock has recorded losses over the past five consecutive trading sessions, reflecting a cumulative return of -9.81% during this period, while underperforming its sector by 2.01% on the day.

Vivo Bio Tech has reached a new 52-week low, reflecting ongoing challenges in its stock performance. The company has underperformed its sector and experienced a decline over the past year. Long-term fundamentals show weak growth and concerns regarding debt servicing, despite recent positive financial results.

Vivo Bio Tech has reached a new 52-week low, reflecting ongoing challenges in its stock performance. The company has underperformed its sector and is trading below key moving averages. Despite recent profit increases, it has reported a decline in net sales and low return on equity over the past five years.